Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Share-based Compensation (2020 - 2025)

Tarsus Pharmaceuticals has reported Share-based Compensation over the past 6 years, most recently at $14.3 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $14.3 million for Q4 2025, up 93.35% from a year ago — trailing twelve months through Dec 2025 was $41.7 million (up 49.97% YoY), and the annual figure for FY2025 was $41.7 million, up 49.97%.
  • Share-based Compensation for Q4 2025 was $14.3 million at Tarsus Pharmaceuticals, up from $12.2 million in the prior quarter.
  • Over the last five years, Share-based Compensation for TARS hit a ceiling of $14.3 million in Q4 2025 and a floor of $1.4 million in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $5.4 million (2023), compared with a mean of $6.0 million.
  • Biggest five-year swings in Share-based Compensation: surged 2233.9% in 2021 and later dropped 14.5% in 2022.
  • Tarsus Pharmaceuticals' Share-based Compensation stood at $4.1 million in 2021, then fell by 11.14% to $3.7 million in 2022, then soared by 49.33% to $5.5 million in 2023, then surged by 35.04% to $7.4 million in 2024, then skyrocketed by 93.35% to $14.3 million in 2025.
  • The last three reported values for Share-based Compensation were $14.3 million (Q4 2025), $12.2 million (Q3 2025), and $8.2 million (Q2 2025) per Business Quant data.